They discovered that the bioactive compound wortmannin possesses anti-oral cancer properties by targeting the hub gene androgen receptor and disrupting the PI3K-AKT pathway (Ladke et al., 2022). This evidence concerns the gene AKT1 and lip and oral cavity carcinoma.